IMMIX BIOPHARMA INC. - COMMON STOCK

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

07 Feb 2024 08:37:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

05 Feb 2024 21:30:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces Proposed Public Offering of Common Stock

05 Feb 2024 14:20:11 By Nasdaq GlobeNewswire

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

24 Jan 2024 07:35:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board

04 Jan 2024 08:34:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board

18 Dec 2023 08:39:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023

11 Dec 2023 08:36:00 By Nasdaq GlobeNewswire

Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit

30 Nov 2023 08:46:00 By Nasdaq GlobeNewswire

Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis

22 Nov 2023 08:19:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing

21 Nov 2023 08:46:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing

21 Nov 2023 08:46:00 By Nasdaq GlobeNewswire

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients

06 Nov 2023 08:12:00 By Nasdaq GlobeNewswire

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients

06 Nov 2023 07:40:00 By Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board

26 Oct 2023 07:58:00 By Nasdaq GlobeNewswire

Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

16 Oct 2023 08:05:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting

03 Oct 2023 08:14:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

02 Oct 2023 07:06:00 By Nasdaq GlobeNewswire

U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis

21 Sep 2023 07:55:00 By Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

19 Sep 2023 08:10:00 By Nasdaq GlobeNewswire

Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference

07 Sep 2023 07:41:00 By Nasdaq GlobeNewswire